Key facts
- It has raised $46.8M; the latest was Later Stage VC ($11.7M) in Oct 2025.
- Notable investors include Bpifrance, INNVIERTE SICC, Asabys Partners, Alta Life Sciences, BCN Health Booster — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ona Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Ona Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ona Therapeutics
Developer of biotechnology therapies designed to discover and develop biologics targeting tumor metastatic-initiating cells and lipid metabolism. The company's therapeutic biologics block the pathways that allow fat metabolism in animal models of cancer and inhibit the cells that give rise to metastases, with the potential to prevent the development of these malignant growths and eliminate existing ones, enabling healthcare institutes to treat various metastatic tumors, including oral, breast, ovarian, gastric, bladder, prostate and melanoma.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2019
- Employees
- 35
- Website
- ona-therapeutics.com/
- Ownership
- Privately Held (backing)
Ona Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ona Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ona Therapeutics in its N-PORT filings yet. We sweep new filings monthly.